Lower Thymosin Beta-4 Levels Predict Worse Outcomes in ICU Patients with Sepsis

This was a prospective observational cohort study of 191 patients admitted to the ICU with sepsis. Tβ4 concentrations were measured in blood samples taken within 6 hours of ICU admission. Patients were divided into tertiles based on Tβ4 levels. Outcomes included acute kidney injury, need for continuous renal replacement therapy, and mortality at 7 and 28 days. Logistic regression was used to calculate odds ratios, and Kaplan-Meier survival analysis assessed time-to-event outcomes. AUC (area under the curve) was calculated for predictive accuracy.

Sepsis kills millions of people annually, and early identification of the highest-risk patients is critical for guiding aggressive treatment. Current biomarkers like procalcitonin and lactate have limitations. Thymosin beta-4 offers a new prognostic tool that reflects the body's anti-inflammatory peptide reserves — lower levels may indicate exhausted protective mechanisms. If validated, Tβ4 testing could help ICU teams make faster decisions about dialysis initiation and treatment escalation.

Thymosin beta-4 is best known in regenerative medicine research for its wound healing and tissue repair properties. This study adds a new dimension by positioning it as a prognostic biomarker in critical care. The finding that lower Tβ4 correlates with worse sepsis outcomes aligns with its known anti-inflammatory role — suggesting that patients whose natural anti-inflammatory peptide reserves are depleted may be more vulnerable to organ damage and death from sepsis.

This is an observational study and cannot prove that low Tβ4 causes worse outcomes — it may simply reflect disease severity. The AUC values (0.68–0.72) indicate moderate, not excellent, predictive accuracy. The study was conducted at a single center with 191 patients, which may limit generalizability. Confounding factors may not be fully controlled. Whether Tβ4 supplementation could improve outcomes was not tested.